$HALO
SEC EDGAR Filings Hub
2 Filings
$HALO · HALOZYME THERAPEUTICS, INC. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for HALOZYME THERAPEUTICS, INC. ($HALO) from November 6, 2026 through November 6, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
Check $HALO portfolio concentration →
View $HALO Congress trades →
Research $HALO stock →
All SEC filings →
Total Filings2
10-K / 10-Q Reports1
8-K Material Events1
Form 4 Insider0
High-Impact1
Latest FilingNovember 6, 2026
Browse SEC Filings by Form Type
Latest $HALO SEC Filings & AI Summaries (2)
November 6, 2026
$HALO 8-K — HALOZYME THERAPEUTICS, INC.
A 39% revenue jump, raised guidance, and a patent injunction against Merck's Keytruda Qlex make this a high-signal quarter for a royalty-compounding platform.
November 5, 2026
$HALO 10-Q — HALOZYME THERAPEUTICS, INC.
A 39% revenue surge paired with a swing to negative stockholders' equity shows aggressive capital return and refinancing offsetting strong operating momentum.
Related & Peer Company SEC Filing Hubs